{
  "source": "PA-Notification-Buphenyl-Olpruva-Pheburane-Na-phenylbutyrate.txt",
  "chunks": [
    "UnitedHealthcare Pharmacy\nClinical Pharmacy Programs\nProgram Number 2025 P 1239-10\nProgram Prior Authorization/Notification\nMedication Buphenyl® (sodium phenylbutyrate), Olpruva®* (sodium\nphenylbutyrate), Pheburane®* (sodium phenylbutyrate), sodium\nphenylbutyrate\nP&T Approval Date 12/2017, 12/2018, 12/2019, 12/2020, 12/2021, 12/2022, 12/2023,\n2/2024, 2/2025\nEffective Date 5/1/2025\n1. Background:\nSodium phenylbutyrate is indicated as adjunctive therapy in the chronic management of patients\nwith urea cycle disorders involving deficiencies of carbamoyl phosphate synthetase (CPS),\nornithine transcarbamylase (OTC), or argininosuccinic acid synthetase (AS). It is indicated in all\npatients with neonatal-onset deficiency (complete enzymatic deficiency, presenting within the\nfirst 28 days of life). It is also indicated in patients with late-onset disease (partial enzymatic\ndeficiency, presenting after the first month of life) who have a history of hyperammonemic\nencephalopathy. Sodium phenylbutyrate must be used with dietary protein restriction and, in\nsome cases, dietary supplements (e.g., essential amino acids, arginine, citrulline, protein-free\ncalorie supplements).\n2. Coverage Criteriaa:\nA. Initial Authorization\n1. Buphenyl, Olpruva*, Pheburane*, or sodium phenylbutyrate will be approved based\non both of the following criteria:\na. Diagnosis of urea cycle disorders (UCDs)\n-AND-\nb. Will be used concomitantly with dietary protein restriction and, in some cases,\ndietary supplements (e.g., essential amino acids, arginine, citrulline, protein-free\ncalorie supplements)\nAuthorization will be issued for 12 months.\nB. Reauthorization\n1. Buphenyl, Olpruva*, Pheburane*, or sodium phenylbutyrate will be approved based\non both of the following criteria:\na. Documentation of positive clinical response to therapy\n-AND-\n© 2025 UnitedHealthcare Services Inc.\n1\nb. Patient is actively on dietary protein restriction and, in some cases, dietary\nsupplements (e.g., essential amino acids, arginin",
    "al response to therapy\n-AND-\n© 2025 UnitedHealthcare Services Inc.\n1\nb. Patient is actively on dietary protein restriction and, in some cases, dietary\nsupplements (e.g., essential amino acids, arginine, citrulline, protein-free calorie\nsupplements)\nAuthorization will be issued for 12 months.\na State mandates may apply. Any federal regulatory requirements and the member specific\nbenefit plan coverage may also impact coverage criteria. Other policies and utilization\nmanagement programs may apply.\n3. Additional Clinical Rules:\n• Notwithstanding Coverage Criteria, UnitedHealthcare may approve initial and re-\nauthorization based solely on previous claim/medication history, diagnosis codes (ICD-10)\nand/or claim logic. Use of automated approval and re-approval processes varies by program\nand/or therapeutic class\n• Supply limits may be in place\n• Olpruva* brand pellets for oral suspension and Pheburane* brand oral pellets are typically\nexcluded from coverage. Tried/Failed criteria may be in place. Please refer to plan specifics\nto determine exclusion status.\n4. References:\n1. Buphenyl® [package insert]. Deerfield, IL: Horizon Therapeutics, Inc.; March 2023.\n2. Olpruva® [package insert]. Newton, MA: Acer Therapeutics, Inc.; December 2022.\n3. Pheburane® [package insert]. Princeton, NJ: Medunik USA, Inc.; August 2023\nProgram Prior Authorization/Notification – Buphenyl® (sodium phenylbutyrate),\nOlpruva™* (sodium phenylbutyrate), Pheburane®* (sodium\nphenylbutyrate), sodium phenylbutyrate\nChange Control\n12/2017 New program\n12/2018 Administrative change to add statement regarding use of automated\nprocesses.\n12/2018 Annual review. No changes to clinical coverage criteria.\n12/2019 Annual review. No changes to clinical coverage criteria.\n12/2020 Annual review. No changes to clinical coverage criteria.\n12/2021 Annual review. No changes to clinical coverage criteria.\n12/2022 Annual review. No changes to clinical coverage criteria. Added state\nmandate and updated reference.\n12/2023 Annu",
    "rage criteria.\n12/2021 Annual review. No changes to clinical coverage criteria.\n12/2022 Annual review. No changes to clinical coverage criteria. Added state\nmandate and updated reference.\n12/2023 Annual review. No changes to clinical coverage criteria. Updated\nreference.\n2/2024 Added Olpruva and Pheburane, including statement that Olpruva and\nPheburane are typically excluded from coverage. Updated references.\n2/2025 Annual review. No changes to clinical coverage criteria.\n© 2025 UnitedHealthcare Services Inc.\n2"
  ]
}